LABT (Lakewood-Amedex Biotherapeutics) Additional Paid-In Capital: $51.58 Mil(As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LABT Lakewood-Amedex Biotherapeutics Inc LABT
8 GF Score
Price $2.37
View Full Analysis

What is Lakewood-Amedex Biotherapeutics Additional Paid-In Capital?

Lakewood-Amedex Biotherapeutics LABT 8 Additional Paid-In Capital is $51.58 Mil as of Mar. 2026. GuruFocus rates LABT with a GF Score™ of 8/100.


Lakewood-Amedex Biotherapeutics's quarterly additional paid-in capital increased from Sep. 2025 ($51.49 Mil) to Dec. 2025 ($51.53 Mil) and increased from Dec. 2025 ($51.53 Mil) to Mar. 2026 ($51.58 Mil).

Lakewood-Amedex Biotherapeutics's annual additional paid-in capital increased from Dec. 2023 ($49.30 Mil) to Dec. 2024 ($50.06 Mil) and increased from Dec. 2024 ($50.06 Mil) to Dec. 2025 ($51.53 Mil).

Lakewood-Amedex Biotherapeutics Additional Paid-In Capital Related Terms

Lakewood-Amedex Biotherapeutics Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for Lakewood-Amedex Biotherapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lakewood-Amedex Biotherapeutics Additional Paid-In Capital Chart

Lakewood-Amedex Biotherapeutics Annual Data
Trend Dec23 Dec24 Dec25
Additional Paid-In Capital
49.30 50.06 51.53

Lakewood-Amedex Biotherapeutics Quarterly Data
Dec23 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Additional Paid-In Capital Get a 7-Day Free Trial 50.06 0.00 51.49 51.53 51.58
LABT
8GF Score
Lakewood-Amedex Biotherapeutics Inc LABT
Additional Paid-In Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lakewood-Amedex Biotherapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of $51.58 Mil mean?
Lakewood-Amedex Biotherapeutics (LABT) has a Additional Paid-In Capital of $51.58 Mil as of Mar. 2026. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Lakewood-Amedex Biotherapeutics and its competitors.
Is Lakewood-Amedex Biotherapeutics' Additional Paid-In Capital too high?
Lakewood-Amedex Biotherapeutics' current Additional Paid-In Capital is $51.58 Mil. Overall, Lakewood-Amedex Biotherapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Lakewood-Amedex Biotherapeutics' Additional Paid-In Capital compare to CDIO and JAGX?
Lakewood-Amedex Biotherapeutics' Additional Paid-In Capital of $51.58 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Biotechnology company?
A good Additional Paid-In Capital depends on the Biotechnology industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Lakewood-Amedex Biotherapeutics and its competitors. Lakewood-Amedex Biotherapeutics's current Additional Paid-In Capital is $51.58 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lakewood-Amedex Biotherapeutics stock overvalued right now?
Lakewood-Amedex Biotherapeutics (LABT) has a current Additional Paid-In Capital of $51.58 Mil. The current Additional Paid-In Capital is $51.58 Mil. Lakewood-Amedex Biotherapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For Lakewood-Amedex Biotherapeutics (LABT), the current Additional Paid-In Capital is $51.58 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lakewood-Amedex Biotherapeutics Business Description

Address 8031 Cooper Creek Blvd, Unit 103, University Park, FL, USA, 34201
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
8GF Score

Get the complete analysis for LABT

Additional Paid-In Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.37
Price